Arvinas, Inc.
Financials
Valuation Metrics
Arvinas, Inc.'s Market Cap is $536M. At end of 2025 it was $770M. Ranked #2769 of 3,121 in US market (top 89%), #1205 of 1,463 on NASDAQ (top 82%), #223 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $536M | US#2,769/3,121 Sec#223/266 |
| Revenue | $317M | US#2,439/3,121 Sec#92/266 |
| Net Income | $9M | US#2,169/3,121 Sec#70/266 |
| Total Assets | $675M | US#2,649/3,121 Sec#136/266 |
| Net Assets | $562M | US#2,158/3,121 Sec#100/266 |
| Employees | 246 | US#2,461/3,121 Sec#123/266 |
| Value | ||
| P/E | 57.65x | US#1,971/3,121 Sec#55/266 |
| P/B | 0.95x | US#339/3,121 Sec#11/266 |
| P/S | 1.69x | US#1,138/3,121 Sec#19/266 |
| EV/EBITDA | 155.20x | US#2,469/3,121 Sec#82/266 |
| FCF Yield | -38.94% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | 1.65% | US#2,050/3,121 Sec#64/266 |
| ROA | 1.38% | US#1,816/3,121 Sec#68/266 |
| Op. Margin | -4.45% | US#2,471/3,121 Sec#84/266 |
| Revenue Growth | -15.05% | US#2,658/3,121 Sec#150/266 |
| Financial Health | ||
| Debt Ratio | 20.08% | US#230/3,121 Sec#78/266 |
| Total Debt | $8M | US#2,860/3,121 Sec#207/266 |
| FCF | $-209M | US#2,783/3,121 Sec#210/266 |
| Cash | $94M | US#2,263/3,121 Sec#181/266 |
| Current Ratio | 7.91x | US#323/3,121 Sec#100/266 |
| Net Debt/EBITDA | -29.69x | US#5/3,121 Sec#1/266 |
| Performance | ||
| 1Y Return | 9.20% | US#1,486/3,121 Sec#170/266 |
| 1M Return | -10.26% | US#2,461/3,121 Sec#188/266 |
| From 52W High | -42.73% | US#2,532/3,121 Sec#202/266 |
| 1Y MDD | -49.53% | US#2,433/3,121 Sec#177/266 |
| Trading | ||
| Volume | 523,045 shares | US#1,977/3,121 Sec#206/266 |
| Trading Value | $4M | US#2,713/3,121 Sec#228/266 |
| Per Share | ||
| EPS | $0.14 | US#2,067/3,121 Sec#67/266 |
| BPS | $8.71 | US#1,933/3,121 Sec#79/266 |
Company Info
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.